BACKGROUND:Cytomegalovirus (CMV) infection can be acquired in utero or postnatally through horizontal transmission and breastfeeding. The effect of postnatal CMV infection on postnatal HIV transmission is unknown. METHODS: The Breastfeeding, Antiretrovirals and Nutrition study, conducted in Malawi, randomized 2369 mothers and their infants to three antiretroviral prophylaxis arms - mother (triple regimen), infant (nevirapine), or neither - for 28 weeks of breastfeeding, followed by weaning. Stored plasma and peripheral blood mononuclear cell specimens were available for 492 infants at 24 weeks and were tested with CMV PCR. Available samples from infants who were CMV PCR-positive at 24 weeks were also tested at birth (N = 242), and from infants PCR-negative at 24 weeks were tested at 48 weeks (N = 96). Cox proportional-hazards models were used to determine if CMV infection was associated with infant morbidity, mortality, or postnatal HIV acquisition. RESULTS: At 24 weeks of age, CMV DNA was detected in 345/492 infants (70.1%); the estimated congenital CMV infection rate was 2.3%, and the estimated rate of CMV infection at 48 weeks was 78.5%. CMV infection at 24 weeks was associated with subsequent HIV acquisition through breastfeeding or infant death between 24 and 48 weeks of age (hazard ratio 4.27, P = 0.05). CONCLUSION: Most breastfed infants of HIV-infected mothers in this resource-limited setting are infected with CMV by 24 weeks of age. Early CMV infection may be a risk factor for subsequent infant HIV infection through breastfeeding, pointing to the need for comprehensive approaches in order to achieve elimination of breastfeeding transmission of HIV.
RCT Entities:
BACKGROUND:Cytomegalovirus (CMV) infection can be acquired in utero or postnatally through horizontal transmission and breastfeeding. The effect of postnatal CMV infection on postnatal HIV transmission is unknown. METHODS: The Breastfeeding, Antiretrovirals and Nutrition study, conducted in Malawi, randomized 2369 mothers and their infants to three antiretroviral prophylaxis arms - mother (triple regimen), infant (nevirapine), or neither - for 28 weeks of breastfeeding, followed by weaning. Stored plasma and peripheral blood mononuclear cell specimens were available for 492 infants at 24 weeks and were tested with CMV PCR. Available samples from infants who were CMV PCR-positive at 24 weeks were also tested at birth (N = 242), and from infants PCR-negative at 24 weeks were tested at 48 weeks (N = 96). Cox proportional-hazards models were used to determine if CMV infection was associated with infant morbidity, mortality, or postnatal HIV acquisition. RESULTS: At 24 weeks of age, CMV DNA was detected in 345/492 infants (70.1%); the estimated congenital CMV infection rate was 2.3%, and the estimated rate of CMV infection at 48 weeks was 78.5%. CMV infection at 24 weeks was associated with subsequent HIV acquisition through breastfeeding or infantdeath between 24 and 48 weeks of age (hazard ratio 4.27, P = 0.05). CONCLUSION: Most breastfed infants of HIV-infected mothers in this resource-limited setting are infected with CMV by 24 weeks of age. Early CMV infection may be a risk factor for subsequent infantHIV infection through breastfeeding, pointing to the need for comprehensive approaches in order to achieve elimination of breastfeeding transmission of HIV.
Authors: G Nigro; A Krzysztofiak; G C Gattinara; T Mango; M Mazzocco; M A Porcaro; S Provvedi; J C Booth Journal: AIDS Date: 1996-09 Impact factor: 4.177
Authors: A Kovacs; M Schluchter; K Easley; G Demmler; W Shearer; P La Russa; J Pitt; E Cooper; J Goldfarb; D Hodes; M Kattan; K McIntosh Journal: N Engl J Med Date: 1999-07-08 Impact factor: 91.245
Authors: S Chandwani; A Kaul; D Bebenroth; M Kim; D D John; A Fidelia; A Hassel; W Borkowsky; K Krasinski Journal: Pediatr Infect Dis J Date: 1996-04 Impact factor: 2.129
Authors: Toni Frederick; James Homans; LaShonda Spencer; Francoise Kramer; Alice Stek; Eva Operskalski; Andrea Kovacs Journal: Clin Infect Dis Date: 2012-06-06 Impact factor: 9.079
Authors: Tatiana M Lanzieri; Sheila C Dollard; Cassandra D Josephson; D Scott Schmid; Stephanie R Bialek Journal: Pediatrics Date: 2013-05-27 Impact factor: 7.124
Authors: Jennifer A Slyker; Barbra Richardson; Michael H Chung; Claire Atkinson; Kristjana H Ásbjörnsdóttir; Dara A Lehman; Michael Boeckh; Vincent Emery; James Kiarie; Grace John-Stewart Journal: AIDS Res Hum Retroviruses Date: 2016-12-06 Impact factor: 2.205
Authors: Athena P Kourtis; Jeffrey Wiener; Tiffany S Chang; Sheila C Dollard; Minal M Amin; Sascha Ellington; Dumbani Kayira; Charles van der Horst; Denise J Jamieson Journal: Clin Vaccine Immunol Date: 2015-09-30
Authors: Nancy A Otieno; Bryan O Nyawanda; Fredrick Otiato; Martina Oneko; Minal M Amin; Michael Otieno; Daniel Omollo; Meredith McMorrow; Sandra S Chaves; Sheila C Dollard; Tatiana M Lanzieri Journal: J Clin Virol Date: 2019-09-17 Impact factor: 3.168